<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703547</url>
  </required_header>
  <id_info>
    <org_study_id>CRZ107432</org_study_id>
    <nct_id>NCT00703547</nct_id>
  </id_info>
  <brief_title>A First Time in Human Study of GSK586529 in Healthy Volunteers</brief_title>
  <official_title>A Single Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK586529 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single blind, randomized, placebo-controlled, crossover study in twenty four healthy male&#xD;
      subjects. Subjects will be divided into two cohorts with alternate panel design. The study is&#xD;
      investigating the safety, tolerability and pharmacokinetics of single oral escalating doses&#xD;
      of GSK586529.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2008</start_date>
  <completion_date type="Actual">April 11, 2008</completion_date>
  <primary_completion_date type="Actual">April 11, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of GSK586529 to determine pharmacokinetic parameters</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary recovery of GSK586529</measure>
    <time_frame>Pre-dose, 0-6, 6-12, 12-24, 24-48, 48-72 and 72-96 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Depressive Disorder and Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Subjects receiving treatment in cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one of the following sequences; ABDF,BADF, BDAF or BDFA (A=Placebo, B= GSK586529 dose 1 (3 milligrams), D = GSK586529 dose 3, F = GSK586529 dose 5).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment in cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one of the following sequences; ACEG,CAEG, CEAG or CEGA (A = Placebo, C= GSK586529 dose 2, E = GSK586529 dose 4, G = GSK586529 dose 6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK586529 capsules</intervention_name>
    <description>GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.</description>
    <arm_group_label>Subjects receiving treatment in cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK586529 tablets</intervention_name>
    <description>GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.</description>
    <arm_group_label>Subjects receiving treatment in cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets and capsules will be provided to subjects.</description>
    <arm_group_label>Subjects receiving treatment in cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males aged 18-45 years, inclusive.&#xD;
&#xD;
          -  Healthy subjects, defined as individuals who are free from clinically significant&#xD;
             illness or disease as determined by their (and familial) medical and psychiatric&#xD;
             history, physical examination, laboratory studies, and other tests.&#xD;
&#xD;
          -  Body weight &gt;/= 50 kg (110 lbs) and BMI within the range 18.5-29.9 kg/m2 inclusive.&#xD;
&#xD;
          -  Demonstrates no evidence of active disease, physical or mental impairment.&#xD;
&#xD;
          -  Self-administered Beck Depression Inventory II scale total score no greater than 9,&#xD;
             and suicide question score of zero.&#xD;
&#xD;
          -  Non-smoker (abstinence from smoking for at least 6 months before the start of the&#xD;
             study).&#xD;
&#xD;
          -  Normal electrocardiogram (subjects must have no clinically significant abnormalities&#xD;
             on a 12-lead ECG and a 24 hour Holter ECG).&#xD;
&#xD;
          -  Read, comprehend, and write English at a sufficient level to complete study-related&#xD;
             materials.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  As a result of any of the medical interview, physical examination, evaluation of&#xD;
             mental state and psychiatric history or screening investigations the physician&#xD;
             responsible considers the subject unfit for the study.&#xD;
&#xD;
          -  The subject has a positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  A positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
&#xD;
          -  The subject has a history of psychiatric illness.&#xD;
&#xD;
          -  Any history of suicidal attempts or behavior.&#xD;
&#xD;
          -  Abuse of alcohol defined as an average weekly intake of greater than 21 units or an&#xD;
             average daily intake of greater than three units..&#xD;
&#xD;
          -  Consumption of grapefruit juice or grapefruit within 14 days prior to the first dose&#xD;
             of study medication.&#xD;
&#xD;
          -  Any subject who is not prepared to eat the standard meals provided by the clinic or is&#xD;
             a vegetarian.&#xD;
&#xD;
          -  Any history of an endocrine disorder including, but not limited to, diabetes or&#xD;
             disorders of the hypothalamus, pituitary, adrenal, or thyroid glands, or gonadal&#xD;
             disorder or dysfunction of the reproductive organs.&#xD;
&#xD;
          -  Clinically significant abnormal; total and free testosterone, LH, FSH, ACTH or&#xD;
             cortisol, or TSH or T4 values at screening/baseline&#xD;
&#xD;
          -  LFTs elevated&#xD;
&#xD;
          -  Any other clinically significant laboratory abnormality&#xD;
&#xD;
          -  The subject has a screening ECG with parameters outside ranges defined in the protocol&#xD;
             will also be excluded.&#xD;
&#xD;
          -  History of long QT syndrome (personal or family) or other cardiac conduction disorder,&#xD;
             or other clinically significant cardiac disease.&#xD;
&#xD;
          -  The subject has received an investigational drug or participated in any other research&#xD;
             trial within 3 months or 5 half-lives, or twice the duration of the biological effect&#xD;
             of any drug(whichever is longer) prior to the first dose of study medication.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John'sWort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication, unless in the opinion of the Investigator and sponsor the&#xD;
             medication will not interfere with the study procedures or compromise subject safety.&#xD;
&#xD;
          -  History or presence of allergy to the study drug or drugs of this class, or a history&#xD;
             of drug or other allergy that, in the opinion of the physician responsible,&#xD;
             contraindicates their participation.&#xD;
&#xD;
          -  Donation of more than 500 mL blood within the 3 months before dosing.&#xD;
&#xD;
          -  An unwillingness of male subjects to abstain from sexual intercourse with pregnant or&#xD;
             lactating women from the time of the first dose of study medication until 90 days&#xD;
             following administration of the last dose of study medication&#xD;
&#xD;
          -  An unwillingness of the male subject to use a condom/spermicide in addition to having&#xD;
             their female partner use another form of contraception if the woman could become&#xD;
             pregnant from the time of the first dose of study medication until 90 days following&#xD;
             administration of the last dose of study medication.&#xD;
&#xD;
          -  Current or recent (within one year) gastrointestinal disease; a history of&#xD;
             malabsorption, esophageal reflux, peptic ulcer disease, irritable bowel syndrome;&#xD;
             frequent (more than once a week) occurrence of heartburn; or any surgical intervention&#xD;
             (e.g., cholecysectomy) which would be expected to influence the absorption of drugs.&#xD;
&#xD;
          -  Average daily caffeine intake equivalent to &gt; 4 cups of coffee or &gt; 6 cups of tea.&#xD;
&#xD;
          -  A semi-supine systolic blood pressure less than 90mmHg or greater than 140mmHg or a&#xD;
             semi-supine diastolic blood pressure of less than 60mmHg or greater than 90mmHg; or a&#xD;
             radial pulse rate less than 40bpm or more than 90bpm.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>June 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

